恩替卡韦治疗乙型肝炎肝衰竭患者临床研究

Investigation of the liver failure patients infected with hepatitis B virus treated with entecavir

目的观察恩替卡韦对乙型肝炎肝衰竭患者的疗效与安全性。方法对30例乙型肝炎肝衰竭患者,在支持治疗基础上予以恩替卡韦每天0.5mg口服,观察服药1年后的生存率、肝功能变化、并发症和血清HBVDNA病毒载量,比较治疗组与对照组治疗的疗效与安全性。结果治疗组与对照组治疗1年生存率分别为70%和43%,治疗组生存率显著高于对照组(x2=4.34,P<0.05),治疗组肝功能和血清HBVDNA病毒载量改善明显优于对照组,且安全性良好。结论恩替卡韦能提高乙型肝炎肝衰竭患者的生存率、促进肝功能恢复,安全有效。

Objective To observe the therapeutic effects and its safety of entecavir on the patients of liver failure with hepatitis B virus infection. Methods The treatment group（ n = 30） were administered 0. 5mg enteeavir orally once daily based upon basic supportive therapy. The survival rate,liver function, complications and serum HBVDNA viral load 1 year after treatment were observed and compared with that of the matched controls. Results The survival rate in the treatment group and control were 70. 00% and 43% respectively and the survival rate of the treatment group was significantly higher than that of the controls （x^2 = 4. 34, P 〈 0. 05 ）. The improvement of liver function and serum HBV DNA viral load at undetectable level at 1 year after therapy in enticavir treatment group was significantly higher than that of controls. Morbidity of complications in the treatment group with a good drug safety was superior to that in controls. Conclusion Entecavir showed its positive effect and safety on the imorovement of the survival rate and the life quality in patients with hepatitis B liver failure.